Sigilon Therapeutics Inc. (SGTX): Price and Financial Metrics
SGTX Price/Volume Stats
| Current price | $22.47 | 52-week high | $28.00 |
| Prev. close | $23.06 | 52-week low | $3.77 |
| Day low | $22.09 | Volume | 83,600 |
| Day high | $23.10 | Avg. volume | 62,902 |
| 50-day MA | $14.79 | Dividend yield | N/A |
| 200-day MA | $9.81 | Market Cap | 56.49M |
SGTX Stock Price Chart Interactive Chart >
Sigilon Therapeutics Inc. (SGTX) Company Bio
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Latest SGTX News From Around the Web
Below are the latest news stories about SIGILON THERAPEUTICS INC that investors may wish to consider to help them evaluate SGTX as an investment opportunity.
Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLYRegulatory and acquisition updates from BioMarin (BMRN) and Sigilon (SGTX) are in focus in the biotech sector. |
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli LillyEli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share. |
Why Is Cormedix (CRMD) Stock Down 23% Today?Cormedix (CRMD) stock is falling hard on Thursday with heavy trading after the company priced a public offering of its shares. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! |
Why Is BioXcel Therapeutics (BTAI) Stock Down 57% Today?BioXcel Therapeutics (BTAI) stock is taking a beating on Thursday after the company released its latest clinical trial data. |
SGTX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -69.83% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -87.32% |
| 2021 | -94.25% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...